Arbutus Preferred Stock And Other Adjustments from 2010 to 2024
| ABUS Stock | USD 2.68 0.01 0.37% |
Preferred Stock And Other Adjustments | First Reported 2010-12-31 | Previous Quarter 14 M | Current Value 10.2 M | Quarterly Volatility 5.6 M |
Check Arbutus Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arbutus main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 701.5 K or Selling General Administrative of 12.2 M, as well as many exotic indicators such as Price To Sales Ratio of 13.01, Dividend Yield of 0.0 or PTB Ratio of 3.72. Arbutus financial statements analysis is a perfect complement when working with Arbutus Biopharma Valuation or Volatility modules.
Arbutus | Preferred Stock And Other Adjustments |
Latest Arbutus Biopharma's Preferred Stock And Other Adjustments Growth Pattern
Below is the plot of the Preferred Stock And Other Adjustments of Arbutus Biopharma Corp over the last few years. It is Arbutus Biopharma's Preferred Stock And Other Adjustments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arbutus Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Preferred Stock And Other Adjustments | 10 Years Trend |
|
Preferred Stock And Other Adjustments |
| Timeline |
Arbutus Preferred Stock And Other Adjustments Regression Statistics
| Arithmetic Mean | 5,939,981 | |
| Geometric Mean | 2,989,159 | |
| Coefficient Of Variation | 94.84 | |
| Mean Deviation | 5,364,246 | |
| Median | 911,000 | |
| Standard Deviation | 5,633,662 | |
| Sample Variance | 31.7T | |
| Range | 13M | |
| R-Value | 0.87 | |
| Mean Square Error | 8.2T | |
| R-Squared | 0.76 | |
| Significance | 0.000022 | |
| Slope | 1,099,058 | |
| Total Sum of Squares | 444.3T |
Arbutus Preferred Stock And Other Adjustments History
About Arbutus Biopharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Arbutus Biopharma income statement, its balance sheet, and the statement of cash flows. Arbutus Biopharma investors use historical funamental indicators, such as Arbutus Biopharma's Preferred Stock And Other Adjustments, to determine how well the company is positioned to perform in the future. Although Arbutus Biopharma investors may use each financial statement separately, they are all related. The changes in Arbutus Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Arbutus Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Arbutus Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Arbutus Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Preferred Stock And Other Adjustments | 14 M | 10.2 M |
Pair Trading with Arbutus Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arbutus Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arbutus Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Arbutus Stock
| 0.49 | GILD | Gilead Sciences Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Arbutus Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arbutus Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arbutus Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arbutus Biopharma Corp to buy it.
The correlation of Arbutus Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arbutus Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arbutus Biopharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arbutus Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Arbutus Biopharma Correlation against competitors. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Arbutus Stock analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stocks Directory Find actively traded stocks across global markets |
Is Arbutus Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.109 | Quarterly Revenue Growth (0.66) | Return On Assets (0.29) | Return On Equity (0.60) |
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.